1. Home
  2. ACAD vs INDV Comparison

ACAD vs INDV Comparison

Compare ACAD & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.16

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Logo Indivior PLC

INDV

Indivior PLC

HOLD

Current Price

$34.38

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACAD
INDV
Founded
1993
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
3.7B
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
ACAD
INDV
Price
$22.16
$34.38
Analyst Decision
Buy
Analyst Count
22
0
Target Price
$30.55
N/A
AVG Volume (30 Days)
1.4M
1.4M
Earning Date
05-06-2026
06-08-2026
Dividend Yield
N/A
N/A
EPS Growth
69.12
8100.00
EPS
2.30
1.64
Revenue
$726,437,000.00
$1,239,000,000.00
Revenue This Year
$18.80
N/A
Revenue Next Year
$11.70
N/A
P/E Ratio
$9.87
$20.90
Revenue Growth
40.45
4.29
52 Week Low
$14.20
$10.91
52 Week High
$28.35
$38.00

Technical Indicators

Market Signals
Indicator
ACAD
INDV
Relative Strength Index (RSI) 50.95 61.93
Support Level $21.51 $33.15
Resistance Level $22.97 $35.75
Average True Range (ATR) 0.66 1.26
MACD 0.08 0.30
Stochastic Oscillator 66.67 80.10

Price Performance

Historical Comparison
ACAD
INDV

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

About INDV Indivior PLC

Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).

Share on Social Networks: